Ten years after its creation in 2005, InnoPharmax was ranked seventh fastest growing technology company in Taiwan in Deloitte’s “Technology Fast 500 Asia Pacific” annual ranking. CS Hsu, founder and president of InnoPharmax, introduces the company’s most fundamental asset - OralPAS®, its unique technology platform, and documents the promising development options he envisions for the company.
You founded InnoPharmax in 2005 after having developed extensive industry experience among local and international biopharmaceutical companies. What has been the vision driving the creation and development of the company over the past decade?
"Our fundamental priority is to advance the clinical development of our long-term projects and bring them to the global market."
